Frequency Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapeutics that activate progenitor cells to treat degenerative diseases. The company's lead product candidate, FX-322, is designed to regenerate damaged auditory cells in the ear, aiming to improve hearing function for individuals with sensorineural hearing loss (SNHL). This condition affects over 90% of people with hearing loss, and FX-322 seeks to address the underlying cause rather than merely amplifying sound, which is the current standard of care.

Operating in the biotechnology and healthcare market, Frequency Therapeutics primarily serves patients suffering from degenerative diseases, particularly those with hearing impairments. The company's business model revolves around the research, development, and clinical testing of its therapeutic candidates. Revenue generation is expected to come from the successful commercialization of these therapies, either through direct sales or partnerships with larger pharmaceutical companies.

Frequency Therapeutics leverages a small molecule approach to activate progenitor cells in specific damaged or injured tissues throughout the body, promoting the creation of healthy, functional tissues and organs. This innovative approach positions the company at the forefront of regenerative medicine, with the potential to transform the treatment landscape for various degenerative conditions.

Keywords: biotechnology, progenitor cells, degenerative diseases, sensorineural hearing loss, FX-322, regenerative medicine, auditory cells, clinical-stage, therapeutic development, healthcare.